Enhancing immunotherapy through PD-L1 upregulation: the promising combination of anti-PD-L1 plus mTOR inhibitors.
Hernández-Prat A, Rodriguez-Vida A, Cardona L, Qin M, Arpí-Llucià O, Soria-Jiménez L, Menendez S, Quimis FG, Galindo M, Arriola E, Salido M, Juanpere-Rodero N, Rojo F, Muntasell A, Albanell J, Rovira A, Bellmunt J.
Hernández-Prat A, et al. Among authors: salido m.
Mol Oncol. 2024 Sep 11. doi: 10.1002/1878-0261.13699. Online ahead of print.
Mol Oncol. 2024.
PMID: 39258533
Free article.